Liver Disease and Cirrhosis

The liver is the body's central metabolic factory — it synthesizes proteins, clears drugs and toxins, makes bile, stores glycogen, and regulates clotting. Because it has enormous reserve and regenerative capacity, liver disease is often silent until a large fraction of function is lost. By the time a patient develops jaundice, ascites, or confusion, the underlying injury may have been progressing quietly for years. Understanding liver disease means learning to read the subtle early signals, to interpret the pattern of "liver function tests," and to anticipate the cascade of complications that follow once scarring — cirrhosis — sets in.

This page walks you from acute inflammation (hepatitis) through chronic scarring (cirrhosis), the mechanics of portal hypertension, and the interpretation of liver biochemistry, so you can reason about a real patient rather than memorize a list.

Learning Objectives

• Distinguish the major causes of acute and chronic hepatitis, including the five hepatitis viruses.
• Explain how chronic injury leads to fibrosis and cirrhosis, and why cirrhosis is (mostly) irreversible.
• Describe the pathophysiology of portal hypertension and its consequences.
• Interpret liver function tests as hepatocellular versus cholestatic versus synthetic-failure patterns.
• Recognize and stage the major complications of cirrhosis and the tools used to prognosticate (Child-Pugh, MELD).
• Apply this knowledge to common clinical presentations and exam vignettes.

Quick Answer

Hepatitis is inflammation of the liver, caused most commonly by viruses (A–E), alcohol, drugs, fat (NAFLD/NASH), and autoimmune disease. Sustained injury of any cause drives hepatic stellate cells to lay down collagen; over years this fibrosis reorganizes the liver into regenerative nodules surrounded by scar — cirrhosis. Cirrhosis raises resistance to portal blood flow, producing portal hypertension, which in turn causes varices, ascites, splenomegaly, and hepatic encephalopathy. "Liver function tests" actually measure two different things: markers of hepatocyte or bile-duct injury (ALT, AST, ALP, GGT, bilirubin) and true synthetic function (albumin, prothrombin time/INR). The dangerous complications of decompensated cirrhosis are variceal bleeding, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, and hepatocellular carcinoma.

Where It Came From

For most of medical history, "dropsy" (ascites) and jaundice were recognized clinical states without a mechanism. The link to the liver's structure came in the early 1800s when René Laennec — better known for inventing the stethoscope — described the shrunken, tawny, nodular liver at autopsy and coined the term cirrhosis, from the Greek kirrhos meaning "orange-tawny," referring to its color. The word describes the appearance, not the cause, which is why "cirrhosis" is an end-stage morphology reached by many roads.

The great puzzle of the 20th century was infectious hepatitis. Physicians had long noticed that jaundice could spread in epidemics (the "catarrhal jaundice" of soldiers) and, disturbingly, that it followed blood transfusions and vaccinations. The turning point came in 1965 when Baruch Blumberg, studying blood proteins across populations, found the "Australia antigen" in the serum of an Australian Aboriginal donor — later shown to be the surface antigen of the hepatitis B virus (HBsAg). This single discovery made blood-bank screening possible, led to the first HBV vaccine, and won Blumberg the Nobel Prize in 1976. Hepatitis A was then distinguished as the fecal-oral, self-limiting "infectious hepatitis." A stubborn third category — "non-A, non-B hepatitis" — caused most transfusion-related liver disease until Michael Houghton, Harvey Alter, and Charles Rice cloned the hepatitis C virus in 1989 (Nobel Prize 2020). The motivation throughout was intensely practical: transfusions were quietly infecting patients, and no one could screen for a virus they could not name. That work transformed hepatitis C from an incurable transfusion hazard into a disease cured in over 95% of patients with modern direct-acting antivirals.

Hepatitis: Acute and Chronic Inflammation

Hepatitis simply means liver inflammation. The key clinical division is acute (self-limited or rapidly resolving, weeks) versus chronic (persisting beyond six months, driving fibrosis).

The five hepatitis viruses are worth knowing cold:

Virus	Transmission	Chronic?	Key points
A (HAV)	Fecal-oral	No	Self-limited; travel/food outbreaks; vaccine available
B (HBV)	Blood, sexual, perinatal	Yes (esp. perinatal)	DNA virus; vaccine available; risk of HCC even without cirrhosis
C (HCV)	Blood (IV drug use, old transfusions)	Yes (most)	Often silent for decades; now curable with DAAs
D (HDV)	Blood; needs HBV to replicate	Yes	Only infects HBV-positive patients; worsens outcome
E (HEV)	Fecal-oral	Usually no	Dangerous in pregnancy; zoonotic in developed countries

Non-viral causes are just as important in practice: alcohol-related liver disease, non-alcoholic fatty liver disease (NAFLD/NASH) — now the fastest-growing cause worldwide, linked to obesity and diabetes — drug-induced liver injury (paracetamol/acetaminophen overdose is the classic acute cause), and autoimmune hepatitis.

A typical acute viral hepatitis runs through a prodrome (malaise, nausea, low-grade fever, right-upper-quadrant discomfort), then an icteric phase with dark urine, pale stools, and jaundice, followed by recovery. Transaminases can climb into the thousands. The clinical worry in any acute hepatitis is acute liver failure: the combination of a rising INR (coagulopathy) and encephalopathy in a patient without prior liver disease is an emergency requiring transplant-center care.

From Fibrosis to Cirrhosis

Whatever the insult, chronic injury activates hepatic stellate cells, which transform into collagen-producing myofibroblasts. The liver's normal delicate scaffold is replaced by bands of scar tissue that trap islands of regenerating hepatocytes into regenerative nodules. This distorted architecture is cirrhosis. Two things go wrong at once: the nodules cannot do the liver's chemistry properly (loss of function), and the scar tissue squeezes the blood vessels running through the liver (portal hypertension).

Cirrhosis is clinically divided into compensated (the liver still copes; the patient may feel well and have near-normal bloods) and decompensated (jaundice, ascites, variceal bleeding, or encephalopathy have appeared). The transition from compensated to decompensated is the single most important prognostic step: median survival drops from over a decade to roughly two years. Early fibrosis is reversible if the cause is removed (stop alcohol, cure HCV, treat HBV), but established cirrhosis with nodules is largely fixed — which is why prevention and early treatment matter so much.

Portal Hypertension and Its Consequences

Blood from the gut and spleen drains into the liver through the portal vein before reaching the systemic circulation. When scar tissue raises resistance, portal pressure rises (measured as the hepatic venous pressure gradient; a gradient above 10 mmHg is clinically significant). The body tries to decompress the system through portosystemic collaterals — veins that reconnect portal and systemic circulation. These produce the classic signs:

• Esophageal and gastric varices — dilated collateral veins that can rupture and cause catastrophic upper-GI bleeding.
• Ascites — fluid in the peritoneal cavity, driven by portal hypertension plus low albumin and salt/water retention via the renin-angiotensin system.
• Splenomegaly with hypersplenism (low platelets).
• Caput medusae — visible periumbilical veins.

Portal hypertension also underlies hepatic encephalopathy: gut-derived toxins, chiefly ammonia, bypass the liver through collaterals and reach the brain.

Reading Liver Function Tests

"LFTs" bundle together markers that answer different questions. Group them mentally:

Injury/damage markers (do NOT measure function):

• ALT and AST — leak from damaged hepatocytes. Very high (thousands) suggests acute hepatocellular injury (viral, ischemic, toxic/paracetamol). An AST:ALT ratio above 2 points toward alcohol.
• ALP and GGT — rise with cholestasis (bile-duct obstruction or damage). ALP alone can come from bone; a raised GGT confirms the ALP is hepatic.
• Bilirubin — rises with hemolysis, impaired conjugation, or cholestasis; causes jaundice.

True synthetic function:

• Albumin — made only by the liver; a low albumin reflects chronic, established disease (though also malnutrition/inflammation).
• Prothrombin time / INR — the liver makes clotting factors with short half-lives, so a rising INR is a sensitive, early marker of failing synthetic function.

Worked example. A 55-year-old man has ALT 60, AST 130, ALP 110, bilirubin 40, albumin 28, INR 1.6. The AST-predominant modest transaminase rise suggests alcohol; the low albumin and raised INR tell you synthetic function is already impaired — this is not a mild acute hepatitis but likely decompensating chronic liver disease. Contrast with a 25-year-old with ALT 3,000, AST 2,800, normal albumin and INR: a big acute hepatocellular hit (viral or toxic) in a previously healthy liver.

Prognosis: Child-Pugh and MELD

Two scores dominate. Child-Pugh grades cirrhosis A/B/C using bilirubin, albumin, INR, ascites, and encephalopathy — easy at the bedside and predicts surgical risk. MELD (Model for End-stage Liver Disease) uses bilirubin, INR, creatinine (and sodium), giving a continuous score used mainly to prioritize liver transplantation. Remember: MELD leans on markers of true function (INR, bilirubin) plus kidney involvement, because hepatorenal syndrome is a lethal endpoint.

Real-World Applications

• Every hospital admission with abnormal LFTs requires the injury-versus-function reasoning above; it changes whether you think "gallstone," "hepatitis," or "failing liver."
• Paracetamol overdose is a leading cause of acute liver failure; recognizing it early allows N-acetylcysteine to prevent it — one of the great time-critical interventions in medicine.
• Screening and vaccination: HBV vaccination is routine childhood immunization; blood-bank screening (a direct legacy of Blumberg and the HCV discovery) has virtually eliminated transfusion hepatitis.
• Public health: NAFLD/NASH now tracks the obesity and diabetes epidemics, making lifestyle counselling a liver intervention, not just a cardiovascular one.

Common Mistakes

1. "LFTs measure liver function." Mostly they do not. ALT/AST/ALP are injury markers. Only albumin and INR (and bilirubin, partly) reflect function. A patient can have normal ALT and a dying liver, or ALT in the thousands with perfectly intact synthetic function.

2. Giving vitamin K or FFP to "correct" the INR in stable cirrhosis before a procedure. The prolonged INR in cirrhosis reflects reduced synthesis of both pro- and anti-coagulant factors, so it does not reliably predict bleeding, and reflexive correction is often unnecessary and can cause harm. Bleeding risk requires clinical judgement, not the INR number alone.

3. Assuming hepatitis C is untreatable or that "cured" hepatitis means no cirrhosis risk. HCV is now curable in the vast majority, but patients who already have cirrhosis remain at risk of hepatocellular carcinoma even after cure and need ongoing surveillance.

Comparison and Connections

Feature	Acute hepatitis	Cirrhosis (chronic)
Onset	Days–weeks	Years
ALT/AST	Often very high	Mildly raised or normal
Albumin/INR	Usually normal	Low albumin, high INR
Reversible?	Often	Largely no
Danger	Acute liver failure	Decompensation, HCC

Do not confuse portal hypertension (a plumbing problem from scarring) with synthetic failure (a chemistry problem from lost hepatocytes) — cirrhosis causes both, but they explain different complications. And separate pre-hepatic jaundice (hemolysis, unconjugated bilirubin) from hepatic and post-hepatic/obstructive (cholestatic, conjugated bilirubin) causes; this drives your whole workup.

Practice Questions

Recall

Q: Which two of the standard LFT panel best reflect the liver's true synthetic function? A: Serum albumin and prothrombin time/INR (both depend on hepatic protein synthesis).

Understanding

Q: Explain why a patient with cirrhosis develops ascites. A: Portal hypertension raises hydrostatic pressure in the splanchnic circulation while reduced albumin lowers oncotic pressure; splanchnic vasodilation triggers renin-angiotensin-aldosterone activation, causing renal sodium and water retention. Together these push fluid into the peritoneal cavity.

Application

Q: A 60-year-old with known cirrhosis presents with fever, abdominal pain, and worsening ascites. What complication must you exclude, and how? A: Spontaneous bacterial peritonitis. Perform a diagnostic ascitic tap; an ascitic neutrophil count of 250 cells/mm³ or more confirms it and mandates antibiotics (and albumin to protect renal function).

Analysis

Q: A patient has ALT 2,500, AST 2,400, INR rising from 1.2 to 2.5 over 48 hours, and new confusion, with no prior liver disease. What is happening and why is it an emergency? A: Acute liver failure — massive hepatocyte necrosis (e.g., paracetamol or acute viral). The rising INR shows collapsing synthetic function and the confusion signals encephalopathy; this combination carries high mortality and requires urgent transfer to a transplant center.

FAQ

Is cirrhosis always caused by alcohol? No. Alcohol is a major cause, but viral hepatitis (B and C), NAFLD/NASH, autoimmune hepatitis, and genetic/cholestatic diseases (hemochromatosis, Wilson disease, primary biliary cholangitis) all cause cirrhosis. Many patients with cirrhosis have never had a heavy drink.

Can the liver really regenerate? Yes — a healthy liver can regrow after partial removal, which is why living-donor transplants are possible. But in cirrhosis the regeneration happens inside a scarred framework, producing nodules rather than restoring normal architecture, so function is not recovered.

Why do people with liver disease bruise and bleed? The liver makes most clotting factors, so synthetic failure prolongs the INR; portal hypertension also lowers platelets via an enlarged spleen. Note, though, that the clotting picture in cirrhosis is a rebalanced, unstable equilibrium — patients can also form clots.

What causes the confusion (encephalopathy)? Toxins normally cleared by the liver — chiefly ammonia from gut bacteria — bypass the failing/shunted liver and affect the brain. Common triggers include GI bleeding, infection, constipation, and dehydration. Lactulose and rifaximin are mainstays of treatment.

Is hepatitis B curable like hepatitis C? Not usually. HCV is curable with direct-acting antivirals in most people. HBV can be effectively suppressed with long-term antivirals (reducing progression and cancer risk) but is rarely fully eradicated, because its DNA persists in liver cells.

Quick Revision

• Hepatitis = liver inflammation; causes = viral (A–E), alcohol, NAFLD/NASH, drugs, autoimmune.
• HBV discovered by Blumberg (Australia antigen, 1965); HCV cloned 1989 — enabled blood screening.
• Chronic injury → stellate cell activation → fibrosis → cirrhosis (nodules + scar).
• Cirrhosis: compensated vs decompensated; decompensation slashes survival.
• Portal hypertension → varices, ascites, splenomegaly, encephalopathy.
• LFTs: ALT/AST/ALP/GGT/bilirubin = injury; albumin + INR = function.
• AST:ALT above 2 hints alcohol; ALT in thousands hints acute viral/toxic.
• Key complications: variceal bleed, SBP, encephalopathy, hepatorenal syndrome, HCC.
• Prognosis: Child-Pugh (bedside), MELD (transplant priority).

Related Topics

Prerequisites

• Gastroenterology overview
• Basic hepatic anatomy and physiology (see ../../2._Physiology/index.md)

Related Topics

• Pharmacology of hepatotoxic drugs and paracetamol overdose (../../5._Pharmacology/index.md)
• Microbiology of the hepatitis viruses (../../6._Microbiology/index.md)

Next Topics

• Hepatocellular carcinoma and liver tumors (../../32._Oncology/index.md)
• Acute upper GI bleeding and endoscopic management (../index.md)